PLXP
Income statement / Annual
Last year (2021), PLx Pharma Inc.'s total revenue was $8.21 M,
an increase of 26,873.38% from the previous year.
In 2021, PLx Pharma Inc.'s net income was -$51.46 M.
See PLx Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$8.21 M |
$30.43 K |
$565.46 K |
$753.11 K |
$778.66 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$4.81 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$3.40 M
|
$30.43 K
|
$565.46 K
|
$753.11 K
|
$778.66 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.41
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$4.18 M
|
$4.34 M
|
$4.74 M
|
$3.92 M
|
$4.16 M
|
$12.75 M
|
$11.29 M
|
$8.90 M
|
$1.73 M
|
$844.63 K
|
| General & Administrative Expenses |
$0.00
|
$9.15 M
|
$10.03 M
|
$7.79 M
|
$10.17 M
|
$8.61 M
|
$7.48 M
|
$4.68 M
|
$2.28 M
|
$999.36 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$40.01 M
|
$9.15 M
|
$10.03 M
|
$7.79 M
|
$10.17 M
|
$8.61 M
|
$7.48 M
|
$4.68 M
|
$2.28 M
|
$999.36 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.29 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$44.19 M
|
$13.49 M
|
$14.77 M
|
$11.71 M
|
$14.33 M
|
$21.37 M
|
$18.76 M
|
$13.58 M
|
$4.01 M
|
$1.84 M
|
| Cost And Expenses |
$49.00 M
|
$13.49 M
|
$14.77 M
|
$11.71 M
|
$14.33 M
|
$21.37 M
|
$18.76 M
|
$13.58 M
|
$4.01 M
|
$1.84 M
|
| Interest Income |
$0.00
|
$0.00
|
$405.24 K
|
$297.80 K
|
$112.38 K
|
$46.77 K
|
$22.06 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.00 K
|
$307.95 K
|
$994.98 K
|
$1.15 M
|
$1.16 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.55 M
|
$415.61 K
|
$405.24 K
|
$200.96 K
|
$746.01 K
|
$46.77 K
|
$22.06 K
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$35.24 M |
-$13.46 M |
-$13.80 M |
$2.24 M |
-$15.10 M |
-$21.32 M |
-$18.74 M |
-$13.58 M |
-$4.01 M |
-$1.84 M |
| EBITDA Ratio |
-4.29
|
-442.3
|
-24.4
|
2.98
|
-19.39
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-4.97
|
-442.3
|
-25.12
|
-14.55
|
-20.35
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$5.34 M
|
-$1.75 M
|
-$6.30 M
|
$11.86 M
|
-$418.89 K
|
$46.77 K
|
$22.06 K
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$46.13 M
|
-$15.21 M
|
-$20.50 M
|
$896.48 K
|
-$16.27 M
|
-$21.32 M
|
-$18.74 M
|
-$13.58 M
|
-$4.01 M
|
-$1.84 M
|
| Income Before Tax Ratio |
-5.62
|
-499.86
|
-36.26
|
1.19
|
-20.89
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$5.34 M
|
-$107.66 K
|
$836.73 K
|
$13.00 M
|
-$920.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$51.46 M
|
-$15.10 M
|
-$21.34 M
|
$896.48 K
|
-$15.35 M
|
-$21.32 M
|
-$18.74 M
|
-$13.58 M
|
-$4.01 M
|
-$1.84 M
|
| Net Income Ratio |
-6.27
|
-496.32
|
-37.74
|
1.19
|
-19.71
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.18 |
-1.55 |
-2.39 |
0.1 |
-2.19 |
-16.45 |
-15.9 |
-13.84 |
-6.94 |
-3.64 |
| EPS Diluted |
-2.18 |
-1.55 |
-2.39 |
0.1 |
-2.19 |
-16.45 |
-15.9 |
-13.84 |
-6.94 |
-3.64 |
| Weighted Average Shares Out |
$23.65 M
|
$9.71 M
|
$8.92 M
|
$8.73 M
|
$7.02 M
|
$1.30 M
|
$1.18 M
|
$981.29 K
|
$577.98 K
|
$507.04 K
|
| Weighted Average Shares Out Diluted |
$23.65 M
|
$9.71 M
|
$8.92 M
|
$8.73 M
|
$7.02 M
|
$1.30 M
|
$1.18 M
|
$981.29 K
|
$577.98 K
|
$507.04 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
